Objective. The aim of this study was to determine the relationship between fusion and adjacent segment disease via Dynesys long-term outcomes. Summary of Background Data. Dynesys is a dynamic stabilization system meant to improve symptoms by stabilizing the spine without fusion and avoiding the development of adjacent segment disease. However, few studies have evaluated long-term outcomes. Methods. All patients were operated on with Dynesys from 2006 to 2009 by a single surgeon at a single institution. We prospectively collected 18 variables among the following categories: patient characteristics, comorbidities, surgical indications, and OR variables. We analyzed two primary endpoints: solid fusion on X-ray and clinical adjacent segment disease (ASD) both at 5 years. Secondary endpoints were time to fusion, time to ASD, reoperation, Oswestry disability index (ODI), and visual analogue scale (VAS) leg pain. We conducted a multivariate analysis via the random forest method. Mann-Whitney U test and Fisher exact test were then used to qualify relationship between variables. Results. We had 52 patients to review in the database. Eight had preexisting ASD. Mean follow-up was 92 months (median 87 months). Fifteen had ASD (29%) during follow-up at a mean 45 months (Median 35 months). Nine had a solid fusion (17%), 2 of which also had ASD. Mean time to fusion was 65 months (median 71 months). Differences in improvement of ODI (P ¼ 0.005) and VAS leg pain (P ¼ 0.002) were significant favoring patients without ASD. The multivariate analysis revealed four variables associated with ASD: prior ASD (OR 11.3, P ¼ 0.005), neurological deficit (OR 8.5, P ¼ 0.018), revision OR (OR 8.5, P ¼ 0.018), and multilevel degeneration (OR 0.184, P ¼ 0.026). No variable was associated with fusion. Conclusion. Dynesys was associated with a high rate of ASD over long-term follow-up despite maintaining a low fusion rate. Prior ASD was the strongest predictor of progressive ASD.
I
n recent years, increasing concerns have arisen with the durability of fusion procedures. Initially described in the 1950s, 1,2 adjacent segment disease (ASD) was then felt to be a relatively uncommon phenomenon. However, in recent years, both the increasing number of fusion procedures being completed as well as increased awareness of ASD have led to its occurrence as a relatively common complication of spinal arthrodesis. 3 Reported incidence for ASD varies substantially depending on the definition used, ranging from 5% to 100%. 4 More specifically, clinical ASD describes symptomatic disease usually due to spinal stenosis at the adjacent segments potentially leading to re-operation. [5] [6] [7] The incidence of clinical ASD is lower, reported to range from 5.2% to 16 .5% at 5 years and 10.6% to 36.1% at 10 years. 4,9 -13 This entity is believed to be secondary to excessive motion at the adjacent segments, 14, 15 although its pathophysiology remains controversial. 16 Another leading theory links it with a patient's propensity to develop degenerative spine disease. 14 
From the
Dynesys (Zimmer Inc, Warsaw, IN) was introduced in 1994 by Gilles Dubois in Toulouse, France. 17 Considered a second-generation dynamic stabilization system, it was designed and introduced based on experience with the Graf ligamentoplasty, 18, 19 which ultimately proved unsuccessful. [20] [21] [22] Rather than locking the facets in extension, Dynesys uses polyurethane spacers, to limit extension, threaded on a cord (Sulene-PET), which controls flexion. 23 The purported benefit of this stabilization system is that it prevents excessive motion without fusing the instrumented segment. 24 As a result, ASD occurrence is said to be reduced due to motion preservation and nonfusion at the index level. 25 Several issues exist with respect to proving the effect of Dynesys on ASD. First, studies evaluating Dynesys include an array of indications for dynamic stabilization. These include disk herniation, 26, 27 degenerative scoliosis, 28, 29 spinal stenosis, 25, [30] [31] [32] spondylolisthesis, [33] [34] [35] [36] [37] [38] back pain, 39, 40 as well as mixed indications. [41] [42] [43] [44] [45] [46] [47] [48] [49] In this context, it becomes difficult to compare the rate of ASD between studies as the presenting symptoms, patient populations, and natural history of the offending pathologies are significantly diverse. Second, the reported follow-up time for the majority of studies examining ASD and Dynesys are quite short compared with the time of onset of ASD. Only three studies report follow-up of 4 or more years, 34, 37, 46 whereas most series describe a median onset of ASD at 61.4 months (43-85 months). 6, [8] [9] [10] 12, 50 Finally, no studies report on the rate of solid fusion and clinical ASD occurrence in the context of Dynesys use. 24, 25 Even the three studies with adequate long-term follow-up do not present data on fusion or clinical ASD. 34, 37, 46 In light of this, we decided to devise a study with narrow surgical indications and longer than 5 years' follow-up to report both on solid fusion and clinical ASD with Dynesys implantation.
MATERIALS AND METHODS
We reviewed a prospectively collected database of consecutive patients from 2006 to 2009 for which the Dynesys system was used. Fifty-two patients over a total of 73 had sufficient information for analysis. The 21 patients excluded had insufficient data or were lost to follow-up. All patients were operated on by a single surgeon at a single institution. No other surgeon at our institution used this system. We collected 18 variables: patient characteristics (age, sex, neurological deficit, smoking, body mass index >35, claudication, scoliosis, spondylolisthesis), comorbidities (medical comorbidities, psychiatric comorbidities, smoking, previous spine operation, revision surgery), surgical indications, and OR variables (operative level(s), associated discectomy, postoperative complications, and length of hospital stay). Previous spine operation was defined as any prior operation not performed by the author (R.H.), where revision OR meant prior spine OR by the same surgeon. Operative level(s) were stratified into specific segments from T12-L1 to L5-S1.
All patients had symptomatic spinal stenosis causing either neurogenic claudication or radicular pain. Indications for surgery included either multilevel degeneration, prior clinical ASD, or spondylolisthesis above or below the index symptomatic level. Indications were devised by the senior surgeon (R.H) to identify patients more likely to be at risk for clinical ASD based on his clinical experience. Prior clinical ASD was defined as symptomatic spinal stenosis at a level above or below a prior fusion operation. Index symptomatic level was defined as primarily radicular pain or neurogenic claudication associated with imaging confirmation of spinal stenosis at that level. Exclusion criteria included spondylolisthesis grade 2 or more, lytic spondylolisthesis, and significant medical comorbidity preventing prone position. All patients were examined by an internal medicine specialist preoperatively. No patient was excluded based on age: 19 patients were in their 80s and one patient was 91 at the time of the operation.
The operative technique was the same as previously described for dynamic stabilization. 51 Fluoroscopy was used for pedicle screw placement. Decompression via laminectomy was performed in every case. No more than one-third of the medial facet was removed. When additional discectomy was performed concurrently as deemed necessary by the surgeon, it was included as a variable in the analysis.
We analyzed two primary endpoints: fusion on X-ray and clinical ASD. Secondary endpoints were time to fusion, time to clinical ASD, reoperation, Oswestry disability index (ODI), visual analogue scale (VAS) leg pain, and VAS back pain. Patient-reported outcomes were collected at baseline and final follow-up at the time of the study. Time to fusion was defined as time from OR to first X-ray showing solid fusion. Time to ASD was defined as time from OR to both clinical symptoms associated with a symptomatic level and radiological confirmation of relevant ASD. Fixed surgical follow-up was at 2 to 3 months and 12 months. Further follow-up was provided by family doctors. Patients were seen again by the surgeon when referred back by their family doctors. Patients were contacted at the time of the study for final follow-up.
We did not hypothesize a set of variables that would be directly predictive of adjacent segment disease or fusion after implementation of the Dynesys system. All data captured for clinical purposes were included in the analysis. The approach implemented was random forest 52 as a multivariate analysis. This statistical tool separates ''signal from noise'' by constructing a ''forest'' of decision trees to identify significant variables. Specifically, a Gini index of >1 was used to discriminate variables warranting further analysis. Mann-Whitney U test and Fisher exact test were then used to qualify the relationship between variables.
RESULTS
Fifty-two patients were reviewed (Table 1) . Three died of unrelated causes during follow-up; however, all patients still had a minimum of 5-year follow-up (62-116 months), with a mean of 92 months (median 87 months). Fifteen patients developed clinical ASD (29%) during the follow-up period at a mean of 45 months (median 35 months). Among those, five underwent reoperation, two declined further operation, four had medical contraindications for further surgery, three are currently undergoing further investigation, and one patient developed failed back syndrome associated with neuropathic pain. Nine patients had a fusion (17%), two of which also developed clinical ASD. The mean time to fusion was 65 months (median 71 months). The correlation between fusion and clinical ASD was nonsignificant (P ¼ 0.7197) Preop mean VAS leg pain for patients with ASD was 9.4 (7-10), which was similar to that of patients without ASD with 9.1 (7-10) (P ¼ 0.30). ODI was also similar for both groups at 49.6 (32-66) for ASD and 51.3 (28-64) for non-ASD (P ¼ 0.63). For patients with ASD, post-op mean VAS leg pain was 6.2 (4-7) and mean ODI was 30.7 . This was compared with patients without ASD with respectively mean VAS leg pain of 2.2 (0-6) and mean ODI was 10.2 (0-38). The improvement in each instance was significant (P < 0.001). The difference between the two groups postoperatively was also significant for VAS leg pain and ODI (P < 0.001 both).
The multivariate analysis revealed older age, operative indication, presence of neurological deficit, increasing length of hospital stay, revision surgery, and increasing surgical levels as the most important variables (Fig. 1) for constructing decision trees with respect to prediction of clinical ASD. Operative indication was further divided in multilevel degeneration, prior ASD and spondylolisthesis.
Further analysis was conducted via Fisher exact test for categorical variables and Mann-Whitney U test for continuous variables (Table 2) . Both age and length of hospital stay were nonsignificant (P ¼ 0.21 and P ¼ 0.294, respectively). Operative indication was significant (P ¼ 0.011). Prior ASD and multilevel degeneration were significant (P ¼ 0.005, OR 11.3 and P ¼ 0.026, OR 0.184, respectively). Spondylolisthesis was nonsignificant (P ¼ 1) (Fig. 2) . Furthermore, neurological deficit was found to be significant (P ¼ 0.018, OR 8.5), in addition to revision surgery (P ¼ 0.018, OR 8.5). Finally, the number of surgical levels was nonsignificant (P ¼ 0.205).
The multivariate analysis revealed the variables (Fig. 3 ) for constructing decision trees with respect to prediction of solid fusion to include: increasing age, increasing length of hospital stay, and number of surgical levels affected. Further analysis via Fisher exact test for categorical variables and Mann-Whitney U test for continuous variables revealed none of these variables to be significant (P ¼ 0.586, P ¼ 0.503, and P ¼ 0.152, respectively) ( Table 3) . Finally, a Kaplan-Meier survival curve was constructed to show the annual progression of both ASD and fusion (Fig. 4) .
DISCUSSION
Soon after its commercial release, studies highlighting Dynesys revealed favorable results, 17,24,26,43,45,61,68 -71 including a multicenter randomized control trial. 42 The initial enthusiasm waned as studies showing negative results were published, 25, [30] [31] [32] 46, [72] [73] [74] and reviews pointing out a lack of evidence for Dynesys in preventing ASD emerged. [75] [76] [77] Finally, the Food and Drug Administration (FDA) advisory committee recommendation against approval of Dynesys 78 severely restricted its use in North America: the largest Dynesys multicenter randomized control trial conducted for FDA approval remains unpublished.
Despite these setbacks, Dynesys remains in use worldwide: recent clinical series from Switzerland, 79 South Korea, 29 and China 27,41,49 all report good short-term outcomes for selected indications. The severity of diseases included is however relatively mild, especially with respect to deformity, 80 limiting the generalizability of these series. Despite this literature, one key question remains unanswered: Does Dynesys achieve his goal of nonfusion in the long term and does it then prevent ASD? Our aim was to conduct a study with narrow surgical indications and longer than 5 years' follow-up to report on long-term outcomes of both on solid fusion and clinical ASD with Dynesys implantation.
Dynesys is a dynamic stabilization system engineered to preserve motion at the instrumented level and prevent fusion. Exactly how much motion is preserved has been a matter of debate, with variable results in vitro [53] [54] [55] [56] [57] [58] [59] [60] and in vivo. 25, [27] [28] [29] 33, 37, 40, 44, 48, 49, 61 Although clinical studies have reported postoperative range of motion via flexionextension X-rays, 29, 34 radiostereometric analysis, 62 and positional MRI, 63 this is the first study to our knowledge reporting the fusion rate. The rationale to use fusion as a primary outcome is Dynesys' stated goal to prevent it, although this objective was not always met. 29 In that regard, the dynamic stabilization system reaches his mark with a low-fusion rate (17%). Furthermore, in the 9 patients wherein fusion occurred, it did so at a mean of 65 months postoperatively. The incidence of new clinical ASD was found to be 29%. In the three Dynesys studies with comparable longterm follow-up, 34, 37, 46 clinical ASD was not reported. However, reoperation rates for ASD were respectively 12%, 34 15%, 37 and 13%, 46 which is comparable with our own rate of 10%. In comparison with the fusion literature, this is at the highest range of reported incidence of clinical ASD at 5.2% to 16.5% at 5 years to 10% to 36.1% at 10 years. 4,8 -12 The annual incidence of clinical ASD in this cohort was found to be 4.5% per year in comparison with previous reports ranging from 0.6% to 3.9% annually. 8, 10, 64, 65 This would suggest that dynamic Our results are in contradiction with two recent metaanalyses, 66, 67 which both found that motion-preserving strategies had statistically significant lower rates of ASD development. Those two articles combined several different motion-preserving strategies for their primary analysis including Dynesys, total lumbar disk replacement, and X-stop. They also used articles with different definitions of ASD, at times combining clinical ASD and radiological ASD. A similar concern arises with length of follow-up, which also varied substantially throughout the articles (2-6 years). We suggest that a narrower scope of analysis with a strict definition of clinical ASD has stronger scientific validity to examine the specific case of Dynesys.
In the Dynesys clinical literature, we are the first to report on preoperative neurological deficit: those were all various degrees of weakness in dorsiflexion and extensor hallux longus or both resulting in partial or complete foot drop. There was also one instance of plantiflexion weakness. The reason this parameter is predictive of clinical ASD (OR 8.5) is unknown. There was no association between neurological deficits and either prior ASD or revision surgery. Our hypothesis that a neurological deficit denotes severe disease needs to be substantiated by further research. Likewise, the finding that multilevel degeneration might be protective (OR 0.184) of clinical ASD development is also new. The definition of multilevel degeneration was based purely on radiological data from the preoperative MRI, and as such has no clear clinical correlate. We hypothesize that multilevel degeneration may result in increased overall stiffness and thus protect the adjacent-level clinical ASD. However, this would require confirmation.
The findings that prior ASD (OR 11.3) and revision surgery (OR 8.5) are predictive of clinical ASD are more intuitive. Of the 8 patients with ASD preoperatively, 6 (75%) developed clinical ASD postoperatively. This was at a different level than the operated segment. Conversely, 5 of the 6 patients undergoing revision surgery were undergoing reoperation due to clinical ASD. This highlights two points: first, the surgeon selected those patients in his practice with clinical ASD to undergo instrumentation with Dynesys; second, ASD seems to develop regardless of intervention. This is the first report, to our knowledge, of recurrent clinical ASD after reoperation.
Our study has several limitations. First, despite the prospective collection of data, we performed a retrospective analysis, which is prone to information bias: the quality of clinical information might differ between patients given complications, reoperations, etc. It is possible the 21 patients with insufficient information in the database had different outcomes. Second, selection bias is another likely confounder. The patients were selected on the basis of having a presumed higher risk of ASD likely resulting in an inflated incidence of clinical ASD. It is entirely possible that a fusion procedure in that context would have yielded an even higher rate of clinical ASD. To truly compare the risk of clinical ASD in Dynesys versus fusion procedures, a case-control study using a matched cohort of selected patients at high risk for ASD undergoing fusion procedures would be necessary and a randomized control trial would be ideal. Third, this is a study conducted at a single institution on patients operated on by a single surgeon. The fact that surgical technique could explain the findings limits the generalizability of this work. Finally, the study of ASD is complicated by the various definitions encountered in the literature. Clinical ASD is generally linked to surgical decision-making, which in itself constitutes an imperfect correlate. 8 Several factors influence surgical decision-making, which we sought to mitigate by including patients offered surgery, but not operated on due to comorbidities or patient choice. We conducted a study examining clinical ASD in the context of the Dynesys stabilization system. This system is associated with a much higher rate of clinical ASD (29%) then previously reported despite maintaining a low fusion rate (17%). We found that nonfusion does not protect against clinical ASD suggesting that factors besides fusion are involved in clinical ASD development. We report several new findings including the correlation between clinical ASD and neurological deficit, prior ASD, and revision surgery, as well as the seemingly protective effect of multilevel degeneration. The natural history of ASD seems to be the most influential factor for clinical progression as 75% of patients with prior ASD had further ASD at another level. 
